HIV Drug Resistance Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland 21702, USA.
J Biol Chem. 2012 Feb 3;287(6):4066-75. doi: 10.1074/jbc.M111.314781. Epub 2011 Nov 21.
The vinylogous urea, NSC727447, was proposed to allosterically inhibit ribonuclease H (RNase H) activity of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) by interacting with the thumb subdomain of its non-catalytic p51 subunit. Proximity of the p51 thumb to the p66 RNase H domain implied that inhibitor binding altered active site geometry, whereas protein footprinting suggested a contribution from α-helix I residues Cys-280 and Lys-281. To more thoroughly characterize the vinylogous urea binding site, horizontal alanine scanning mutagenesis between p51 residues Lys-275 and Thr-286 (comprising α-helix I and portions of the neighboring αH/αI and αI/αJ connecting loops) was combined with a limited vertical scan of Cys-280. A contribution from Cys-280 was strengthened by our observation that all substitutions at this position rendered selectively mutated, reconstituted p66/p51 heterodimers ∼45-fold less sensitive to inhibition. An ∼19-fold reduced IC(50) for p51 mutant T286A coupled with a 2-8-fold increased IC(50) when intervening residues were substituted supports our original proposal of p51 α-helix I as the vinylogous urea binding site. In contrast to these allosteric inhibitors, mutant enzymes retained equivalent sensitivity to the natural product α-hydroxytropolone inhibitor manicol, which x-ray crystallography has demonstrated functions by chelating divalent metal at the p66 RNase H active site. Finally, reduced DNA strand-transfer activity together with increased vinylogous urea sensitivity of p66/p51 heterodimers containing short p51 C-terminal deletions suggests an additional role for the p51 C terminus in nucleic acid binding that is compromised by inhibitor binding.
拟似物尿嘧啶 NSC727447 通过与非催化 p51 亚基的拇指结构域相互作用,被提议变构抑制人类免疫缺陷病毒 1 型逆转录酶(HIV-1 RT)的核糖核酸酶 H(RNase H)活性。p51 拇指与 p66 RNase H 结构域的接近表明抑制剂结合改变了活性位点的几何形状,而蛋白质足迹分析表明 α-螺旋 I 残基半胱氨酸 280 和赖氨酸 281 有贡献。为了更彻底地描述拟似物尿嘧啶结合位点,对 p51 残基 Lys-275 和 Thr-286(包含 α-螺旋 I 和相邻的 αH/αI 和 αI/αJ 连接环的部分)之间的水平丙氨酸扫描突变与 Cys-280 的有限垂直扫描相结合。我们观察到,在这个位置的所有取代都使选择性突变的、重组的 p66/p51 异源二聚体对抑制的敏感性降低了约 45 倍,这加强了 Cys-280 的作用。与 p51 突变体 T286A 相关的 IC50 降低了约 19 倍,而插入残基取代时的 IC50 增加了 2-8 倍,这支持了我们最初提出的 p51 α-螺旋 I 作为拟似物尿嘧啶结合位点的观点。与这些变构抑制剂相反,突变酶对天然产物 α-羟基三酮抑制剂马尼科尔保持相同的敏感性,X 射线晶体学已经证明该抑制剂通过螯合 p66 RNase H 活性位点的二价金属发挥作用。最后,p66/p51 异源二聚体的 DNA 链转移活性降低,以及含有短 p51 C 端缺失的 p66/p51 异源二聚体对拟似物尿嘧啶的敏感性增加,表明 p51 C 端在核酸结合中具有额外的作用,而抑制剂结合会损害这种作用。